Please login to the form below

Not currently logged in
Email:
Password:

Tesaro

This page shows the latest Tesaro news and features for those working in and with pharma, biotech and healthcare.

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

in the face of competition from newer market entrants Rubraca (rucaparib) from Clovis Oncology and Johnson &Johnson/Tesaro’s Zejula (niraparib). ... Tesaro and Clovis will report fourth quarter results this week.

Latest news

More from news
Approximately 6 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 339. TeneoBio/TESARO. Multi-specific antibodies for up to six undisclosed oncology targets using UniRat® platform and discovery engine TeneoSeek.

  • Deal Watch February 2017 Deal Watch February 2017

    There has been speculation for several months that oncology company Tesaro may be the target for a large pharma bid and as a result its share price has increased by 570%

  • Deal Watch April 2016 Deal Watch April 2016

    Apart from the 3 deals by Abbvie, there were deals by GSK and Janssen with Zymeworks and Tesaro respectively. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for treatment of prostate cancer.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    350.5. AnaptysBio/ Tesaro. Collaboration, licence. mAbs to activate immune system response "checkpoints" - 3 targets: TIM-3, LAG-3 and PD-1 (preclinical).

  • Pharma deals during March 2014 Pharma deals during March 2014

    The second deal, the $341m discovery transaction between AnaptysBio and Tesaro, is focused on the development of antibodies that activate immune checkpoints disabled by various cancers.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics